Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Study of Vandetanib in Patients With Non-small Cell Lung Cancer Harboring RET Rearrangement

NCT01823068 is registered in ClinicalTrials.gov with Samsung Medical Center as lead sponsor.

NCT NCT01823068
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01823068 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Study of Vandetanib in Patients With Non-small Cell Lung Cancer Harboring RET Rearrangement
Lead sponsor
Samsung Medical Center
Phase
Phase 2
Overall status
Completed
Start date
November 3, 2014
Completion date
March 16, 2018
Enrollment
17 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

non small cell lung cancer